RFK Jr. said his agency will find the cause of autism. These researchers have actually been looking
The annual meeting of the International Society for Autism Research took place in Seattle this week.
The field's premiere scientific conference was scheduled to be held in the Emerald City five years ago, until COVID-19 dashed those plans. This time, U.S. autism researchers face a very different kind of crisis: massive cuts to federal funding, Cabinet members making false statements about the complex neurological condition they study, and a series of confusing and potentially worrisome policy announcements about autism research.
In April, the U.S. Department of Health and Human Services disclosed that it's planning a $50-million 'comprehensive research effort aimed at understanding the causes of [autism spectrum disorder] and improving treatments,' a department spokesperson said. The effort was spurred by Secretary Robert F. Kennedy Jr.'s stated goal of determining the cause of autism, a neurological and developmental condition whose symptoms cluster around challenges with communication, social interaction and sensory processing.
At his first news conference last month, Kennedy made a number of scientifically inaccurate statements about autism: that it is preventable (there is no evidence that it is); that studying its genetic underpinnings is a 'dead end' (genes play a significant role); that children with autism "will never hold a job" (autism presents in myriad different ways and many autistic people work) and, perhaps most significantly, that 'we know it's an environmental exposure' (this is, to put it mildly, far from an established fact.)
On Thursday, an HHS spokesperson said that the agency was developing 'a secure data repository' of 'large-scale, de-identified data to better understand the causes of conditions like autism and chronic diseases,' similar to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.
This was a clarification of National Institutes of Health Director Dr. Jay Bhattacharya's statement during an April 21 meeting with NIH advisors that the study would draw in part from personal health information gathered across a variety of sources, including insurance claims, pharmacy chain medication records and fitness tracker data, a plan widely reported as an 'autism registry.'
HHS has otherwise offered minimal detail on the research effort, which Kennedy initially said would return results as early as September. (Bhattacharya has since pushed back on that timeline, saying that grants would only start to go out to participating researchers by the end of summer.)
A half-dozen senior scientists interviewed for this article said that neither they nor anyone they knew of had been consulted.
'I'm someone who knows a lot of people in this field,' said Helen Tager-Flusberg, professor emerita at Boston University and director of its Center for Autism Research Excellence, and 'not a single person I know has been approached.'
Tager-Flusberg is a member of HHS' Interagency Autism Coordinating Committee, which advises the agency and Congress on autism research. Since Trump took office in January, she said, the committee has not received any communications from HHS, and has not been informed or consulted about the latest research initiative.
'With one hand, [Kennedy's] offering $50 million in new research, and with the other hand, they have already removed a significantly large number of grants that are already carrying out cutting-edge research on autism,' she said. 'NIH has invested hundreds of millions of dollars into [studying] causes of autism over the last three decades, and so it's disturbing to hear that it's all being dismissed.'
The U.S. government is by far the nation's biggest investor in autism research. In 2019 and 2020, the most recent period for which data are available, federal grants totaling $350 million supported 82.5% of U.S. autism research, with the remainder coming from private sources.
'Federal funding is the engine by which research runs, and it is certainly the engine by which autism research has made the incredible advances that it has over the last 25 years,' said Matthew Lerner, an associate professor at Drexel University's AJ Drexel Autism Institute and a board member of the International Society for Autism Research.
Several researchers also said that they found Kennedy's insistence that autism stems from exposure to an undetermined environmental source perplexing. The role of environmental factors in autism is already a major focus area for government-funded research, they said, albeit in a more nuanced way.
When scientists speak of 'environmental exposures,' they are referring to any nongenetic influence before or after birth. These can range from prenatal stress hormones to neighborhood pollutants to the school a child attends.
'Any scientist will tell you that this is such a complex thing that you can't just be looking at one [cause], that you have to be thinking about the role of environment, the role of genetics, how they interact, and how that changes over the lifespan,' said Alycia Halladay, chief science officer of the nonprofit Autism Science Foundation. 'We do know that there are a lot of environmental exposures that have not been studied. We can't say it is an environmental toxin.'
Dr. Shafali Jeste was more blunt.
'This is what we dedicate our lives to,' the Los Angeles pediatric neurologist said. 'If we knew there could be one environmental cause, wouldn't we all be out there hunting for it, and maybe having already found it, given that we've been doing research for 20 years?'
The cuts and chaos of the second Trump administration are already having an affect on the research community.
Several people interviewed for this article asked not to be quoted by name for fear of retaliation, or specified that they could only speak on behalf of themselves and not their employer, at the institution's request.
In late April, Tager-Flusberg founded the Coalition of Autism Scientists, a group of senior researchers united around the shared goals of pushing back on disinformation and advocating for evidence-based research approaches.
More than 200 fellow scientists signed up immediately, she said. But when younger researchers have asked to join, she has discouraged them from doing so. Speaking out could cost them their jobs.
'I don't really have anything to lose,' she said. But 'the last thing I would want is to put anyone's career in jeopardy.'
This story originally appeared in Los Angeles Times.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration


Newsweek
an hour ago
- Newsweek
The Bulletin June 4, 2025
The rundown: Health and Human Services Secretary Robert F. Kennedy Jr.'s vow to "Make America Healthy Again" could fall short when it comes to chronic disease, experts have warned. Here's how. Why it matters: Nearly 130 million Americans are estimated to have at least one form of chronic disease, which could be heart disease, cancer, diabetes, obesity or hypertension, according to the Centers for Disease Control and Prevention. The proposed cuts to Medicaid funding and work requirements for eligibility to the benefits, which are set to come as part of the broader GOP budget bill, could leave many with chronic disease without access to vital care. As many as three in four adults enrolled in Medicaid report having one or more chronic conditions, and many are unable to work the hours needed to meet the new eligibility requirements, according to nonprofit health policy research and news organization, KFF. So, while some may be medically exempt, others will lose their health coverage, meaning their conditions could worsen without access to care. Read more in-depth coverage: Health Experts Call Out RFK Jr. Policy Changes: 'New Inconsistency Every Day' TL/DR: Experts told Newsweek that, while the Trump administration's ambition to "defeat" the "epidemic" is clear, whether its policies will help or hinder chronic-disease patients remains to be seen. What happens now? Ross Brownson, director of the Prevention Research Center at Washington University in St. Louis, Missouri, told Newsweek that Medicaid cuts would "likely have a detrimental effect on chronic disease risk among the most vulnerable populations," adding Medicaid-enrolled adults have significantly higher rates of chronic disease than individuals privately insured. Deeper reading Can Trump Tackle US 'Chronic Disease Crisis'? Experts Weigh In


Hamilton Spectator
3 hours ago
- Hamilton Spectator
Who makes decisions for public health is changing in Hamilton
Community members are now at Hamilton's public health decision-making table after long-awaited governance reform got the green light from the province. 'I think it's so vitally important to have those voices there,' Coun. Cameron Kroetsch said in an interview with The Spectator. 'I think, also, it just frankly gives the community more confidence that we have both councillors and health experts who can give a balanced perspective.' Public health policy will no longer be decided by the 16 members of Hamilton's city council after legislative changes passed third reading on June 3 and received royal assent on June 5 as part of Bill 11 , More Convenient Care Act. Instead, six appointed community members , with health expertise or lived experience, will work alongside six city councillors and one education representative to oversee public health. Coun. Cameron Kroetsch says it is 'vitally important' to have community voices on the board of health. The Progressive Conservative government made the required amendments to the City of Hamilton Act at council's request. 'The community pushed really hard for this,' Kroetsch said. 'It's been a long journey.' City council will provide one final approval at its meeting on June 18 but the vote is considered a formality. The new board is expected to meet for the first time on July 7 — over four years after calls for change started in March 2021 when COVID-19 brought inequities, related to social determinants of health, to the forefront as some groups fared better than others during the pandemic. Advocates — including doctors, social workers and academics — argued for a board of health that better reflects Hamilton's diversity, including racialized residents and those with disabilities. 'We didn't have that kind of community voice available to respond to issues of public health in our city and so I think this is going to be great,' Kroetsch said. 'Having these key people around the table, we learned during COVID, would have made things so much better … I just can't say enough about how important I think it is for community voices to be at the table.' The changes bring Hamilton more in line with about two-thirds of the province's public health units that are overseen by autonomous boards. Hamilton's board will be semi-autonomous as decisions related to the budget, the annual service plan and the appointment of medical officers of health will still be approved by city council. Toronto and Ottawa also have semi autonomous boards. However, policy decisions would no longer need any further approval so the board's vote would be binding. 'There's not really a way for council to override the board of health,' Kroetsch said. 'We've given over that autonomy.' The governance reform initially had the unanimous support of council in January 2024. While awaiting the legislative changes, a public health subcommittee was created that will now become the board of health. Up until now, its decisions needed to be approved by city councillors. But opposition to the changes flared up in May after a disagreement over how restrictive the city should be about drinking on municipal property revealed a divide between councillors and the subcommittee. The proposed changes to the municipal alcohol policy were passed with almost no discussion by the subcommittee. In stark contrast, councillors voted 13-1 against it after a charged debate and an in-camera session to get legal advice. It raised questions about what would happen in the future when the semi-autonomous board of health no longer needed councillors' approval for such policy decisions. The subsequent vote went from unanimous to passing 9-5 on the makeup of the future board of health. But Kroetsch, who has been chairing the subcommittee, expects the transition will now be smooth. 'It's just going to be a new day for Hamilton in terms of having that expert advice from the community on the board of health to be able to weigh in on matters that are important,' Kroetsch said. 'We're talking about something that has literally a life and death impact for people. Public health is one of those areas of municipal governance that can impact people's day to day lives.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .